Literature DB >> 19817712

The CX(3)C-chemokine fractalkine in kidney diseases.

M J Koziolek1, R Vasko, C Bramlage, G A Müller, F Strutz.   

Abstract

The chemokine CX(3)C-L/FKN is expressed in both soluble and transmembrane/mucin hybrid forms, thus combining chemoattractant functions together with receptor/adhesion molecule properties. In contrast to other chemokine receptors, CX(3)C-R is expressed not only on lymphoid cell populations, but also on several intrinsic cells including tubular epithelial cells and renal fibroblasts where it regulates various aspects of cell viability, matrix synthesis and degradation, migration, inflammation as well as oxidative stress. In the kidney, the chemokines/receptor pair has been shown to play a role in nephrogenesis as well as in the pathogenesis primary and secondary nephropathies. In several animal models and human specimens with acute and chronic renal failure including allograft nephropathy, CX(3)C-L/CX(3)C-R has been shown to exert immune and non-immune mediated renal damages. A blockade of this chemokine system ameliorated acute and chronic renal damages, though the latter to a more robust extent. There seems to a role of the CX(3)C-L/CX(3)C-R pair in mediating acute renal inflammation as well as in progressive chronic renal failure. However, functional studies are lacking for many aspects and further studies are necessary to better define the functional properties of CX(3)C-L/FKN and its receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19817712     DOI: 10.2174/138955709789055252

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  3 in total

Review 1.  The immune system and developmental programming of brain and behavior.

Authors:  Staci D Bilbo; Jaclyn M Schwarz
Journal:  Front Neuroendocrinol       Date:  2012-09-09       Impact factor: 8.606

2.  Methylprednisolone attenuates lipopolysaccharide-induced Fractalkine expression in kidney of Lupus-prone MRL/lpr mice through the NF-kappaB pathway.

Authors:  Yanwu You; Yueqiu Qin; Xu Lin; Fafen Yang; Jun Li; Suren R Sooranna; Liao Pinhu
Journal:  BMC Nephrol       Date:  2015-08-27       Impact factor: 2.388

Review 3.  CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?

Authors:  Quan Zhuang; Ke Cheng; Yingzi Ming
Journal:  Curr Gene Ther       Date:  2017       Impact factor: 4.391

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.